Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -
Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Tuesday, December 2, 2008
Switching first-line disease-modifying therapy after failure
Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E.
Multiple Sclerosis Center, Department of Neurology, University of California, San Francisco, California, USA; Department of Neurological and Vision Sciences, University of Verona, Verona, Italy.
Background - Options for non-responders to relapsing-remitting multiple sclerosis (RRMS) first-line disease-modifying therapies (DMT) are limited. We explored whether switching first-line DMT is effective.MethodsPatients with RRMS who first received interferon-beta (IFNB) or glatiramer acetate (GA) were classified in three categories: DMT change because of suboptimal response, DMT change because of other reasons, and no DMT change during follow-up.
Suggestions, Comments and/or Questions are always appreciated.. - Thank you